Enoby™ REMS FDA Required REMS Safety Information

Enoby™ (denosumab-qbde)

January 2026

Important Safety Update

Dear Bone Health and Osteoporosis Foundation:

The FDA has required Hikma Pharmaceuticals USA Inc. to distribute this safety update to your organization as part of our Enoby REMS (**R**isk **E**valuation and **M**itigation **S**trategy). We request that you inform your members about the following **serious risk of Enoby**.

Severe Hypocalcemia in Patients with Advanced Kidney Disease

Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m^2), including dialysis-dependent patients, are at a greater risk of severe hypocalcemia following Enoby administration.

- Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported.
- To minimize the risk of hypocalcemia in patients with advanced chronic kidney disease (CKD):
  - Evaluate for the presence of chronic kidney disease mineral and bone disorder (CKD-MBD) with intact parathyroid hormone (iPTH), serum calcium, 25(OH) vitamin D, and 1,25 $(OH)_2$ vitamin D prior to decisions regarding Enoby treatment.
  - Consider assessing bone turnover status (serum markers of bone turnover or bone biopsy) to evaluate the underlying bone disease that may be present.
  - Monitor serum calcium weekly for the first month after Enoby administration and monthly thereafter.
  - Coordinate care with healthcare providers with expertise in CKD-MBD for patients with advanced chronic kidney disease.

Role of the Healthcare Provider

- ✓ **Provide** each patient with a copy of the **Patient Guide**.
- ✓ **Review** information in the **Patient Guide** with each patient, including the serious risk of Enoby and the symptoms of severe hypocalcemia.
- ✓ **Advise** each patient to seek prompt medical attention if they have signs or symptoms of severe hypocalcemia.

This letter does not contain the complete safety profile for Enoby. Please review the Prescribing Information enclosed. All Enoby REMS materials are also available at www.enobyrems.com or by contacting your local Hikma Sales Representative.

Reporting Adverse Events

To report Adverse Reactions with Enoby, please call Hikma Pharmaceuticals USA Inc. at 1-877-845-0689, or report the event at FDA MedWatch.

Sincerely,

Hikma Pharmaceuticals USA Inc. – Injectables and Biosimilars